Handel wiąże się z ryzykiem
Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej.
Handel wiąże się z ryzykiem
Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej.
Blueprint Medicines Corp
Closed
SectorHealthcare
101.56 2.51
Overview
Share price change
24h
Min
97.61
Max
101.99
Income | 50M 496K |
|---|---|
Sales | 3M 149M |
EPS | -0.294 |
Profit margin | 0.332 |
Employees | 682 |
EBITDA | -14M -41M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +28.12% upside |
Next Earnings | 31 lip 2025 |
|---|
Market Cap | 763M 6.5B |
|---|---|
Previous open | 99.05 |
Previous close | 101.56 |
News Sentiment
By Acuity
32%
68%
96 / 382 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Blueprint Medicines Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Blueprint Medicines Corp Forecast
Price Target
By TipRanks
28.12% upside
12 Months Forecast
Average 127.47 USD 28.12%
High 155 USD
Low 93 USD
Based on 16 Wall Street analysts offering 12 month price targets forBlueprint Medicines Corp - Dist in the last 3 months.
Sentiment
By Acuity
96 / 382 Ranking in Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
